February 21, 2025Scientific ReportsOpen Access

Metabolic dysfunction associated steatotic liver disease is associated with atrial fibrillation recurrence following cryoballoon ablation

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Atrial fibrillation (n=303). Intervention: Metabolic dysfunction-associated steatotic liver disease (MASLD) vs. No MASLD. Primary outcome: Atrial fibrillation recurrence (HR 2.24, 95% CI 1.35-3.74, p=0.002).

View Full Paper

Ask AI

Bookmark

Key result

MASLD linked to a ~124% greater risk of AF recurrence following cryoballoon ablation.

HR 2.24
95% CI 1.35-3.74
P=0.002
n=303

Why the study?

The impact of Metabolic-associated fatty liver disease (MASLD) on atrial fibrillation recurrence after cryoballoon ablation was unclear.

Does the presence of MASLD increase the risk of atrial fibrillation recurrence in patients undergoing cryoballoon ablation?

Population

303 patients undergoing cryoballoon ablation for atrial fibrillation

Comparison

Presence of MASLD vs absence of MASLD

Design

Cohort study

Follow-up

Median 14 months

Authors

YWYu WangGuangzhou Sport University ZCZheng ChenBeijing Sanbo Brain Hospital RZRuixin ZhangMinistry of Education of the People's Republic of China

Discussion

Member takes

Implication

MASLD association with post-cryoballoon AF recurrence remains uncertain; hypothesis-generating and requires prospective confirmation before clinical consideration.

Study Design

Type

Cohort (n=303)

Multicenter

Structured PICO

Does the presence of MASLD increase the risk of atrial fibrillation recurrence in patients undergoing cryoballoon ablation?

Population

303 adult patients with atrial fibrillation undergoing initial cryoballoon ablation, free of prior ablation, followed for a median of 14 months.

Exposure

Presence of Metabolic-associated fatty liver disease (MASLD), defined by a fatty liver index ≥ 60

Comparator

Absence of MASLD

Outcome

Atrial fibrillation recurrence post-ablation

Main Result

Hazard Ratio: 2.24 (95% CI 1.35–3.74)

Absolute Event Rate: 45.1% vs 20.7%

p-value: p=0.002

MASLD is significantly associated with an increased risk of AF recurrence following cryoballoon ablation, suggesting a need for targeted metabolic interventions periprocedurally.

Limitations

Hepatic steatosis was defined using the fatty liver index (FLI) rather than liver biopsy or imaging.
Potential residual confounding despite controlling for a wide range of confounders.
Assessment of MASLD was conducted only at baseline, with a lack of data on exposure durations and changes during follow-up.
Observational nature precludes establishment of causality.

Cite This Study

Wang et al. (2025) conducted a cohort in Atrial fibrillation (n=303). Metabolic dysfunction-associated steatotic liver disease (MASLD) vs. No MASLD was evaluated on Atrial fibrillation recurrence (HR 2.24, 95% CI 1.35-3.74, p=0.002). Metabolic dysfunction-associated steatotic liver disease independently predicted a significantly higher risk of atrial fibrillation recurrence following cryoballoon ablation (HR 2.24).

synapsesocial.com/papers/6ab1ec9e2c74425994de3f37 https://doi.org/10.1038/s41598-025-90667-z

Topics

Atrial fibrillation Persistent AF management AF ablation outcomes

View Full Paper

Ask AI

Bookmark

Implication

MASLD association with post-cryoballoon AF recurrence remains uncertain; hypothesis-generating and requires prospective confirmation before clinical consideration.

Metabolic dysfunction associated steatotic liver disease is associated with atrial fibrillation recurrence following cryoballoon ablation

Discussion

Member takes

Implication

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Topics

Metabolic dysfunction associated steatotic liver disease is associated with atrial fibrillation recurrence following cryoballoon ablation

Discussion

Member takes

Implication

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Topics

Also Consider